FIELD: medicine, polypeptides.
SUBSTANCE: invention relates to fusion polypeptides with enhanced pharmacokinetic properties. Fusion polypeptides comprising enhancing peptide sequences associated with the core polypeptide possess with the enhanced pharmacokinetic properties, such as prolonged half-time period. Also, invention relates to methods for enhancing pharmacokinetic properties of any core polypeptide by binding the enhancer peptide sequences with the core polypeptide. Proposed core polypeptides can comprise any pharmacologically useful peptide that can be used, for example, the therapeutic or prophylactic agent. The advantage of invention involves the enhancing of pharmacokinetic properties of polypeptides.
EFFECT: enhanced pharmacokinetic properties of polypeptides.
52 cl, 18 dwg, 14 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HYBRID POLYPEPTIDES WITH IMPROVED PHARMACOKINETIC PROPERTIES | 1999 |
|
RU2236865C2 |
| PHARMACEUTICAL COMPOUNDS FOR OPTIMISED INJECTION OF gp41 HIV DERIVED PEPTIDES AND THEIR THERAPEUTIC APPLICATION | 2003 |
|
RU2357749C2 |
| CONJUGATES CONSISTING OF POLYMER AND PEPTIDES DERIVING FROM gp41 HIV AND THEIR USING IN THERAPY | 2003 |
|
RU2317997C2 |
| METHODS AND COMPOSITION FOR INHIBITION OF HIV-1 MULTIPLICATION | 2001 |
|
RU2275379C2 |
| APPLICATION OF COMPOSITION CONSISTING OF CATIONIC LTP PEPTIDE AND MOLECULES OF RNA AGAINST RESPIRATORY VIRUSES | 2015 |
|
RU2609857C1 |
| PEG-CONTAINING POLYPEPTIDE T1249 | 2003 |
|
RU2294938C2 |
| MUTANT POLYMERASES OF HEPATITIS B VIRUS | 2012 |
|
RU2625021C2 |
| METHODS OF USING INTERLEUKIN-10 FOR TREATING DISEASES AND DISORDERS | 2014 |
|
RU2679889C2 |
| LIPOPEPTIDE FOR EFFECTIVE INHIBITION OF HIV, DERIVATIVE THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 2017 |
|
RU2741123C1 |
| IMMUNOGENS FOR VACCINATION AGAINST HIV | 2013 |
|
RU2648791C2 |
